Questions Remain For Samsung Bioepis Post-Biogen

Management Changes, Strategic Focus And Structural Aspects Yet To Be Decided

In exclusive comments made to Generics Bulletin, Samsung Biologics has acknowledged that it has yet to decide on several aspects of Samsung Bioepis’ management, structure and strategic focus once Biogen completes the sale of its stake in the biosimilars joint venture to its partner.

Question mark maze labyrinth
The future path for Samsung Bioepis is not yet fully decided • Source: Cagkan Sayin / Alamy Stock Photo

Questions remain over the path forward for Samsung Bioepis once current partner Biogen sells its stake in the biosimilars joint venture to Samsung Biologics, the Korean company has acknowledged in comments to Generics Bulletin.

Certain details of Samsung Bioepis’ management, structure and strategic focus are yet to be decided, Samsung Biologics confirmed, responding to...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.